Tyra Biosciences/$TYRA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tyra Biosciences
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
- Ticker
- $TYRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 87
- Headquarters
- Carlsbad, United States
- Website
- tyra.bio
Tyra Biosciences Metrics
BasicAdvanced
$1.5B
-
-$2.40
0.73
-
Price and volume
Market cap
$1.5B
Beta
0.73
52-week high
$40.65
52-week low
$13.35
Average daily volume
685K
Financial strength
Current ratio
14.905
Quick ratio
14.478
Long term debt to equity
0.014
Total debt to equity
0.016
Profitability
EBITDA (TTM)
-159.922
Management effectiveness
Return on assets (TTM)
-28.46%
Return on equity (TTM)
-45.31%
Valuation
Price to book
3.63
Price to tangible book (TTM)
3.63
Price to free cash flow (TTM)
-12.108
Free cash flow yield (TTM)
-8.26%
Free cash flow per share (TTM)
-1.778
Growth
Earnings per share change (TTM)
34.46%
3-year earnings per share growth (CAGR)
26.21%
What the Analysts think about Tyra Biosciences
Analyst ratings (Buy, Hold, Sell) for Tyra Biosciences stock.
Analyst projections of the future price of Tyra Biosciences stock.
Bulls say / Bears say
In SURF302, the 60 mg dose produced a 79% overall response rate and a 64% best overall complete response rate among 14 evaluable patients. Tyra plans to discuss the results with regulators and prepare a registrational Phase 3 study, giving its lead programme a potential route towards approval. (U.S. Securities and Exchange Commission)
Dabogratinib showed a potentially useful safety profile for long-term oral treatment: no Grade 4 or 5 events were reported, and no Grade 3 treatment-related events occurred in the 60 mg group. This could help distinguish it from less selective FGFR medicines if the finding holds in larger trials. (U.S. Securities and Exchange Commission)
Tyra reported $353.9 million in cash, cash equivalents and marketable securities at the end of June 2026, which it expects to fund operations into the second half of 2028. That gives the company time to advance several clinical programmes and reach upcoming data readouts without an immediate need for new financing. (Tyra Biosciences)
The 60 mg group’s 57% complete response rate at three months fell short of analyst expectations of roughly 70% to 80%; Tyra’s shares fell nearly 18% after the results. The data therefore delivered a less convincing efficacy signal than investors had hoped for. (BioSpace)
SURF302’s results are still based on a small, early dataset: just 14 patients at 60 mg were evaluable for efficacy, and the company says responses may change with further follow-up. The strongest response finding was in a subgroup of only eight patients, leaving efficacy across a broader patient population and response durability uncertain. (U.S. Securities and Exchange Commission)
Tyra has no marketed product revenue and reported a $45.6 million net loss in the second quarter of 2026, while research and development spending rose to $39.2 million. Its expanded at-the-market programme allows up to $250 million in additional share sales, creating a risk of dilution as it funds costly trials. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2026.
Tyra Biosciences Financial Performance
Revenues and expenses
Tyra Biosciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Tyra Biosciences News
AllArticlesVideos
Funds containing Tyra Biosciences
Fund name | Fund size | $TYRA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.08% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.